天域生物(603717) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥123,298,080.72, a decrease of 38.69% compared to the same period last year[4] - The total profit for the quarter was -¥19,173,115.50, reflecting a decline of 254.11% year-on-year[4] - The net profit attributable to shareholders was -¥12,428,911.08, a significant decrease of 7,912.82% compared to the previous year[4] - The net profit excluding non-recurring gains and losses was -¥14,856,098.85, with a year-to-date decrease of 1,201.31%[4] - The basic earnings per share for the quarter was -¥0.043, a decrease of 178.47% compared to the same period last year[5] - The diluted earnings per share for the quarter was also -¥0.043, reflecting a similar decline of 178.47% year-on-year[5] - The weighted average return on equity was -2.43%, a decrease of 2.45 percentage points compared to the previous year[5] Assets and Liabilities - Total assets at the end of the quarter were ¥2,993,661,485.46, down 6.88% from the end of the previous year[5] - The equity attributable to shareholders was ¥517,715,741.11, a slight decrease of 0.20% compared to the previous year[5] - The company's total liabilities as of September 30, 2025, were CNY 2,287,335,577.61, compared to CNY 2,506,452,041.54 at the end of 2024, indicating a reduction of about 8.7%[19] - The total assets of the company decreased to CNY 2,993,661,485.46 as of September 30, 2025, down from CNY 3,214,984,288.09 at the end of 2024, indicating a decline of approximately 6.9%[19] Cash Flow - The cash flow from operating activities for the year-to-date was ¥147,211,536.83, an increase of 39.90%[4] - The company's cash and cash equivalents decreased to CNY 145,924,090.03 as of September 30, 2025, from CNY 178,048,527.26 at the end of 2024, reflecting a decline of approximately 18.0%[17] - The total cash and cash equivalents at the end of the period decreased to CNY 78,681,406.32 from CNY 115,160,450.82, a decline of 31.7%[29] - The company experienced a net cash outflow from financing activities of CNY -101,406,021.68, compared to CNY -23,938,126.12 in the previous year[29] - The investment activities generated a net cash outflow of CNY -67,463,775.81, compared to CNY -61,213,199.64 in the same period last year[29] Shareholder Information - The company reported a total of 21,713,000 common shares outstanding at the end of the reporting period[12] - Major shareholder Luo Weiguo holds 37,251,829 shares, representing 12.84% of total shares, with 22,000,000 shares pledged and 14,375,524 shares frozen[12] - Major shareholder Shi Dongwei holds 32,338,800 shares, representing 11.15% of total shares, with 29,000,000 shares pledged and 3,181,856 shares frozen[12] - Shenzhen Zeyuan Private Securities Fund Management Co., Ltd. holds 22,000,000 shares, representing 7.58% of total shares[12] - The company has undergone a change in actual control, with Luo Weiguo becoming the sole actual controller after the termination of the concerted action agreement with Shi Dongwei[14] - As of August 25, 2025, Shi Dongwei has irrevocably agreed to waive all voting rights associated with his 32,338,800 shares[14] - The report indicates that there are no significant changes in the shareholding structure of the top 10 shareholders[14] - The total number of shares held by the top 10 unrestricted shareholders remains unchanged[14] Future Plans and Investments - The company plans to issue up to 71,028,297 A-shares to Shanghai Daoyun Asset Management Co., Ltd., raising a total of no more than CNY 465.2353 million, which will be used for working capital and debt repayment[15] - The company is in the process of issuing A-shares, pending approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission[15] Research and Development - Research and development expenses rose to CNY 11,407,398.61, an increase of 72.5% compared to CNY 6,607,811.49 in the same period last year[24] Financial Expenses - The company reported a significant increase in financial expenses, totaling CNY 31,050,606.74, compared to CNY 9,137,237.34 in the previous year, marking a rise of 239.5%[24] Overall Performance - For the first three quarters of 2025, total operating revenue was CNY 535,601,036.79, down approximately 14.2% from CNY 624,472,530.50 in the same period of 2024[22] - Total operating costs for the first three quarters of 2025 were CNY 567,048,150.94, a decrease of about 4.7% compared to CNY 594,720,864.52 in the previous year[22] - The net profit for the first three quarters of 2025 is CNY 10,668,058.84, a decrease of 60.9% compared to CNY 27,281,131.61 in the same period of 2024[24] - The total revenue from operating activities for the first three quarters of 2025 is CNY 765,216,638.76, down from CNY 834,739,497.39 in 2024, representing a decline of 8.3%[27] - The basic and diluted earnings per share for the first three quarters of 2025 were both CNY -0.0031, compared to CNY 0.0220 in the same period of 2024[24]